LL-37

LL-37 is a 37-amino-acid human cathelicidin-derived host-defense peptide supplied in a 5 mg lyophilized format for controlled antimicrobial, innate-immunity, chemotaxis, epithelial-cell, and endothelial research.

• 5 mg lyophilized research peptide

• 37-amino-acid LL-37 sequence

• Approximate molecular weight of 4,493 Da

• ≥95% HPLC-verified purity

• Third-party tested

• Certificate of Analysis documentation available upon request

• Store at 2°C – 8°C or below, desiccated and protected from light

For laboratory research only. Not intended for human or animal consumption, administration, medical treatment, veterinary use, diagnostic use, supplement use, cosmetic use, household use, or personal use.

LL-37 is a synthetic 37-amino-acid research peptide corresponding to the active C-terminal region released from the human cathelicidin precursor protein hCAP18.

LL-37 is classified as a cationic, amphipathic host-defense peptide. Published laboratory research has examined its interactions with microbial membranes, bacterial lipopolysaccharide, immune cells, epithelial cells, endothelial cells, and multiple intracellular signalling pathways.

Experimental studies have evaluated LL-37 in antimicrobial susceptibility assays, membrane-permeabilization models, leukocyte-chemotaxis experiments, cytokine-response studies, epithelial migration and wound-closure assays, and angiogenesis-related models.

LL-37 activity is highly dependent on factors such as peptide concentration, microbial strain, ionic conditions, serum, cell type, receptor expression, and experimental design. Research findings should not be interpreted as evidence of established therapeutic effectiveness or suitability for personal use.

BioVault Labs supplies LL-37 in a 5 mg lyophilized research format with ≥95% HPLC-verified purity. The product is third-party tested, and available Certificate of Analysis documentation may be requested directly from our team.